Your shopping cart is currently empty

Gabapentin enacarbil (XP-13512) is a prodrug for the anticonvulsant and analgesic gabapentin, offering sustained dose-proportional exposure and predictable bioavailability.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | - | In Stock | |
| 5 mg | $81 | In Stock | In Stock | |
| 10 mg | $129 | In Stock | In Stock | |
| 25 mg | $289 | - | In Stock | |
| 50 mg | $463 | - | In Stock | |
| 100 mg | $742 | - | In Stock | |
| 200 mg | $987 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | - | In Stock |
| Description | Gabapentin enacarbil (XP-13512) is a prodrug for the anticonvulsant and analgesic gabapentin, offering sustained dose-proportional exposure and predictable bioavailability. |
| In vitro | Gabapentin enacarbil demonstrated active apical to basolateral transport across Caco-2 cell monolayers and pH-dependent passive permeability across artificial membranes. XP13512 inhibited uptake of (14)C-lactate by human embryonic kidney cells expressing monocarboxylate transporter type-1, and direct uptake of prodrug by these cells was confirmed using liquid chromatography-tandem mass spectrometry. XP13512 inhibited uptake of (3)H-biotin into Chinese hamster ovary cells overexpressing human sodium-dependent multivitamin transporter (SMVT) [1]. |
| In vivo | In 4 studies of healthy volunteers (136 subjects total), the pharmacokinetics of Gabapentin enacarbil immediate- and extended-release formulations were compared with those of oral gabapentin. Gabapentin enacarbil immediate-release (up to 2800 mg single dose and 2100 mg twice daily) was well absorbed (>68%, based on urinary recovery of gabapentin), converted rapidly to gabapentin, and provided dose-proportional exposure, whereas absorption of oral gabapentin declined with increasing doses to <27% at 1200 mg. Compared with 600 mg gabapentin, an equimolar Gabapentin enacarbil extended-release dose provided extended gabapentin exposure (time to maximum concentration, 8.4 vs 2.7 hours) and superior bioavailability (74.5% vs 36.6%) [2]. |
| Synonyms | XP-13512 |
| Molecular Weight | 329.39 |
| Formula | C16H27NO6 |
| Cas No. | 478296-72-9 |
| Smiles | CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 |
| Relative Density. | 1.134 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 95 mg/mL (288.41 mM), Sonication is recommended. DMSO: 95 mg/mL (288.41 mM), Sonication is recommended. H2O: 0.6 mg/mL (1.82 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.02 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/Ethanol/DMSO
Ethanol/DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.